Repotrectinib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 101 publications

Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours.

Repotrectinib is a next-generation TKI for NTRK fusion-positive solid tumours.

Journal: Nature reviews. Clinical oncology

Published: February 18, 2026

Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.

Case report: successful use of repotrectinib in a ROS1 fusion-positive lung adenocarcinoma patient with severe renal insufficiency and prior tyrosine kinase inhibitor treatment failure.

Journal: Anti-cancer drugs

Published: February 11, 2026

Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC.

Effectiveness and cost-effectiveness of first-line versus second-line use of repotrectinib in the treatment of ROS1 fusion-positive advanced NSCLC.

Journal: Expert review of anticancer therapy

Published: January 09, 2026

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; encorafenib for colorectal cancer, daratumumab for multiple myeloma, repotrectinib for NTRK-fusion positive solid tumors, and venetoclax for leukemia.

Journal: International journal of clinical oncology

Published: December 15, 2025

Rare but not forgotten: Therapeutic advancements for rare childhood cancers.

Rare but not forgotten: Therapeutic advancements for rare childhood cancers.

Journal: Molecular therapy. Oncology

Published: December 01, 2025

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.

Lorlatinib in Tyrosine Kinase Inhibitor-Naive Advanced ROS1-Positive Non-Small Cell Lung Cancer: A Phase 2 Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: November 26, 2025

Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases.

Corticosteroids for Managing TRK Inhibitor Withdrawal Pain: A Report on Two Cases.

Journal: Current oncology (Toronto, Ont.)

Published: November 18, 2025

Three novel concomitant NTRK2 fusions in medullary thyroid carcinoma with diagnostic implications.

Three novel concomitant NTRK2 fusions in medullary thyroid carcinoma with diagnostic implications.

Journal: Discover oncology

Published: November 06, 2025

ROS1-positive non-small cell lung cancer: from genomics to treatment decisions.

ROS1-positive non-small cell lung cancer: from genomics to treatment decisions.

Journal: Frontiers in oncology

Published: November 04, 2025

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

KRAS-Wild Pancreatic Cancer-More Targets than Treatment Possibilities?

Journal: Cancers

Published: October 29, 2025

From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy.

From class effects to specificity FAERS evidence and network mapping of adverse events in NSCLC targeted therapy.

Journal: International journal of surgery (London, England)

Published: October 17, 2025

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.

Evolving Therapeutic Landscape of ROS1-Positive Non-Small Cell Lung Cancer: An Updated Review.

Journal: Current oncology (Toronto, Ont.)

Published: October 15, 2025

Showing 1-12 of 101

Last Updated: 04/28/2026